🇺🇸 Rezolute, Inc.RZLT

Company Update Form 8-K 13-11-2026 06:27:13 EST

Subject: 8-K Items 7.01, 8.01, 9.01

Overview: Rezolute announced preliminary positive results from its Phase 3 upLIFT study, with 13 of 16 participants meeting the primary efficacy endpoint for ersodetug.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest